Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estr
 

Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.

More...